[go: up one dir, main page]

ES2425298R1 - PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METASTASIS - Google Patents

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METASTASIS

Info

Publication number
ES2425298R1
ES2425298R1 ES201230195A ES201230195A ES2425298R1 ES 2425298 R1 ES2425298 R1 ES 2425298R1 ES 201230195 A ES201230195 A ES 201230195A ES 201230195 A ES201230195 A ES 201230195A ES 2425298 R1 ES2425298 R1 ES 2425298R1
Authority
ES
Spain
Prior art keywords
treatment
metastasis
pharmaceutical compositions
mannoprotein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201230195A
Other languages
Spanish (es)
Other versions
ES2425298B1 (en
ES2425298A2 (en
Inventor
Echevarria Fernando Hernando
Garcia Andoni Ramirez
Fernando Vidal-Vanaclocha
Arteche Lorea Mendoza
Escobal Natalia Gallot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euskal Herriko Unibertsitatea
Original Assignee
Euskal Herriko Unibertsitatea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euskal Herriko Unibertsitatea filed Critical Euskal Herriko Unibertsitatea
Priority to ES201230195A priority Critical patent/ES2425298B1/en
Publication of ES2425298A2 publication Critical patent/ES2425298A2/en
Publication of ES2425298R1 publication Critical patent/ES2425298R1/en
Application granted granted Critical
Publication of ES2425298B1 publication Critical patent/ES2425298B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas para el tratamiento de la metástasis. La presente invención se relaciona con el empleo de un compuesto con capacidad de unión a una manoproteína y bloquear la unión de dicha manoproteína a un receptor de las células endoteliales, en la elaboración de una composición farmacéutica para el tratamiento de una enfermedad asociada a una adhesión celular indeseada. Asimismo, la presente invención también contempla métodos dirigidos a identificar un compuesto potencialmente útil para la prevención y/o el tratamiento de una enfermedad asociada a una adhesión celular indeseada, a pronosticar la probabilidad de un paciente que padece cáncer a sufrir metástasis y a diseñar una terapia personalizada a un paciente que padece cáncer.Pharmaceutical compositions for the treatment of metastasis. The present invention relates to the use of a compound capable of binding to a mannoprotein and blocking the binding of said mannoprotein to an endothelial cell receptor, in the preparation of a pharmaceutical composition for the treatment of an adhesion-associated disease. unwanted cell phone Likewise, the present invention also contemplates methods aimed at identifying a compound potentially useful for the prevention and / or treatment of a disease associated with unwanted cell adhesion, to predict the probability of a patient suffering from cancer to metastasize and to design a therapy. personalized to a patient suffering from cancer.

ES201230195A 2009-04-02 2009-04-02 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METALASIS Active ES2425298B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201230195A ES2425298B1 (en) 2009-04-02 2009-04-02 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METALASIS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230195A ES2425298B1 (en) 2009-04-02 2009-04-02 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METALASIS

Publications (3)

Publication Number Publication Date
ES2425298A2 ES2425298A2 (en) 2013-10-14
ES2425298R1 true ES2425298R1 (en) 2013-11-08
ES2425298B1 ES2425298B1 (en) 2014-10-01

Family

ID=49231804

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230195A Active ES2425298B1 (en) 2009-04-02 2009-04-02 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METALASIS

Country Status (1)

Country Link
ES (1) ES2425298B1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153361A1 (en) * 2003-09-09 2005-07-14 Sullivan Dianne C. Therapeutic and diagnostic applications of protein disulphide isomerases
WO2006110814A2 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153361A1 (en) * 2003-09-09 2005-07-14 Sullivan Dianne C. Therapeutic and diagnostic applications of protein disulphide isomerases
WO2006110814A2 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bertram G. et al. Structure and regulation of the Candida albicans ADH1 gene encoding an immunogenic alcohol dehydrogenase. Yeast. 1996, Vol. 12, páginas 115-127 (todo el documento) *
Klotz S. A. et al. Antibodies to a5b1 and avb3 integrins react with Candida albicans alcohol dehydrogenase. Microbiology. 2001, Vol. 147, páginas 3159-3164 (todo el documento) *
Orozco A. S. et al. Mechanisms of the proinflammatory response of endotelial cells to Candida albicans infection Infection and Immunity. 03.2000, Vol. 68, Nº3, páginas 1134-1141, ISSN 0019-9567/00 (todo el documento) *
Polonelli L. et al. Antibody Complementarity-Determining Regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. Plos ONE. 06.2008, Vol. 3, Nº 6, e2371 (todo el documento) *

Also Published As

Publication number Publication date
ES2425298B1 (en) 2014-10-01
ES2425298A2 (en) 2013-10-14

Similar Documents

Publication Publication Date Title
IL261348A (en) An isolated antibody or fragment thereof that binds cd100, for use in the treatment of an autoimmune disease, an inflammatory disease of cancer
GT200800250A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
CL2009000402A1 (en) Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others.
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
CL2007003341A1 (en) COMPOUNDS DERIVED FROM IMIDAZOTRIAZINAS; PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF CANCER, ARTEROSCLEROSIS AND CARDIOVASCULAR DISEASES BETWEEN OTHERS.
CL2007002667A1 (en) Use of trastuzumab for the prevention or reduction of metastasis in a patient suffering from her2 positive cancer, who does not respond to monotherapy with trastuzumab or monotherapy with pertuzumab.
CL2008003798A1 (en) Compounds derived from substituted aromatic heterobicycles, py3 kinase inhibitors; pharmaceutical composition; Useful in the treatment of cancer, melanomas, glioblastomas, among other diseases.
MX2010006823A (en) Methods for the treatment of gout.
EA201270619A1 (en) USE OF BETANEHOL FOR THE TREATMENT OF XEROSTOMY
EA201101117A1 (en) DPP-4 INHIBITORS FOR THE TREATMENT OF DIABETES IN CHILDREN
MX2009006704A (en) New compounds.
MX338754B (en) HUMAN ANTIBODIES AGAINST TISSULAR FACTOR.
CL2010001474A1 (en) Compounds derived from thiophene or substituted thiazole, pi3k inhibitors; pharmaceutical composition; Useful in the treatment of cancer, inflammation and in the treatment of cardiovascular disorders.
GEP20135829B (en) C-met antagonist and aminoheteroaryl compound combination for cancer treatment
AR077866A1 (en) COMBINATION THERAPY OF A CD20 AFUCOSILATED AND BENDAMUSTINE ANTIBODY
DOP2012000006A (en) GPR119 AGONIST
CL2008001373A1 (en) Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
MX2009006034A (en) Antagonist antibodies against ephb3.
ES2530428T3 (en) Methods and compositions for the treatment of antibody-mediated neuropathies
CL2011000165A1 (en) Compounds derived from indolinones; pharmaceutical composition comprising said compound; and use of the compound for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
UY32822A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS
CR20110262A (en) MATERIALS TO CREATE WATER SOLUBLES
EA201690964A1 (en) COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR PHENOMENA
CL2008001728A1 (en) Compounds derived from indolinones; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cancer, infections, inflammatory and autoimmune diseases.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2425298

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141001